Xilio Therapeutics (XLO) News Today → Biden to Drop BOMBSHELL June 13th? (From Paradigm Press) (Ad) Free XLO Stock Alerts $1.12 +0.03 (+2.75%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 3:13 PM | investorplace.comXLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024May 14 at 7:30 AM | globenewswire.comXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial ResultsMay 13 at 2:25 AM | americanbankingnews.comXilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest UpdateApril 17, 2024 | msn.comXilio Therapeutics (XLO) Price Target Increased by 17.86% to 5.61April 12, 2024 | stocknews.com3 Biotech Stocks to Invest In Right Now for Long-Term GainsApril 4, 2024 | insidertrades.comGilead Sciences, Inc. Buys 485,250 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) StockApril 2, 2024 | investorplace.comXLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023April 1, 2024 | globenewswire.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial ResultsMarch 29, 2024 | marketwatch.comXilio Shares Take Flight Premarket After Gilead DealMarch 28, 2024 | investorplace.comWhy Is Xilio Therapeutics (XLO) Stock up 168% Today?March 28, 2024 | marketwatch.comXilio Therapeutics Plans Private Placement, Job CutsMarch 28, 2024 | markets.businessinsider.comXilio Prices Private Placement Of $11.3 Mln Of Shares, Updates XTX202 Trial; To Axe 21% Of JobsMarch 28, 2024 | marketbeat.comTrading was temporarily halted for "XLO" at 09:03 AM with a stated reason of "LULD pause."March 28, 2024 | marketbeat.comTrading was temporarily halted for "XLO" at 09:03 AM with a stated reason of "LULD pause."March 28, 2024 | globenewswire.comXilio Therapeutics Announces $11.3 Million Private Placement Equity FinancingMarch 28, 2024 | marketbeat.comTrading was temporarily halted for "XLO" at 06:03 AM with a stated reason of "News pending."February 28, 2024 | globenewswire.comXilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | morningstar.comXilio Therapeutics Inc XLOJanuary 31, 2024 | finance.yahoo.comXilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology ConferenceJanuary 8, 2024 | finance.yahoo.comXilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology TherapiesDecember 28, 2023 | seekingalpha.comWerewolf Therapeutics: Still In The Race To Develop Next Generation CytokinesDecember 7, 2023 | finance.yahoo.comXilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy DataNovember 10, 2023 | msn.comXilio Therapeutics GAAP EPS of -$0.61November 9, 2023 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNovember 8, 2023 | markets.businessinsider.comPromising Clinical Trials and Potential Therapies Propel Buy Rating for Xilio TherapeuticsNovember 3, 2023 | finance.yahoo.comXilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid TumorsOctober 31, 2023 | finance.yahoo.comXilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual MeetingSeptember 27, 2023 | finance.yahoo.comXilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingSeptember 5, 2023 | markets.businessinsider.comXilio Therapeutics Appoints Katarina Luptakova As CMOSeptember 5, 2023 | finance.yahoo.comXilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceSeptember 5, 2023 | finance.yahoo.comXilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development OfficerAugust 18, 2023 | finance.yahoo.comQ2 2023 Xilio Therapeutics Inc Earnings CallAugust 14, 2023 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comXilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating OfficerJuly 20, 2023 | uk.finance.yahoo.comXLO - Xilio Therapeutics, Inc.May 25, 2023 | finance.yahoo.comXilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid TumorsMay 12, 2023 | msn.comChardan Capital Reiterates Xilio Therapeutics (XLO) Buy RecommendationMay 10, 2023 | msn.comXilio Therapeutics GAAP EPS of -$0.83 beats by $0.06May 9, 2023 | finanznachrichten.deXilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial ResultsMay 9, 2023 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial ResultsApril 3, 2023 | finance.yahoo.comXilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 2, 2023 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial ResultsFebruary 27, 2023 | finance.yahoo.comXilio Therapeutics to Present at Upcoming Investor ConferencesFebruary 16, 2023 | finance.yahoo.comXilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership SummitFebruary 2, 2023 | finance.yahoo.comXilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology DayJanuary 27, 2023 | marketbeat.comXilio Therapeutics, Inc. (NASDAQ:XLO) Sees Significant Decrease in Short InterestXilio Therapeutics, Inc. (NASDAQ:XLO - Get Rating) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 19,200 shares, a decline of 31.4% from the December 31st total of 28,000 shares. Based on an average daily volume of 35,800 shares, the short-interest ratio is currently 0.5 days. Currently, 0.2% of the company's shares are sold short.January 26, 2023 | finance.yahoo.comInstitutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the mostJanuary 25, 2023 | seekingalpha.comXLO Xilio Therapeutics, Inc.January 25, 2023 | finance.yahoo.comThese 2 ‘Strong Buy’ Penny Stocks Are on Track for Massive Gains, Say AnalystsNovember 23, 2022 | finance.yahoo.comXilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12 Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden to Drop BOMBSHELL June 13th? (Ad)Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th! Click here now to see his shocking evidence. XLO Media Mentions By Week XLO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XLO News Sentiment▼-0.340.54▲Average Medical News Sentiment XLO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XLO Articles This Week▼60▲XLO Articles Average Week Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IMRX News Today SNSE News Today RMTI News Today HCWB News Today LEXX News Today NXTC News Today UNCY News Today OCUP News Today CARA News Today CLNN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XLO) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 AI Stocks to Buy for 2024Market Moving TrendsThis unknown company solves the biggest issue with AIManward PressTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
